Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway

American Journal of Pathology

Volumn 162, Issue 2, 2003, Pages 655-663

  Steiner, Hannes ^a   Godoy Tundidor, Sonia ^a   Rogatsch, Hermann ^b   Berger, Andreas P ^a   Fuchs, Dietmar ^b   Comuzzi, Barbara ^a   Bartsch, Georg ^a   Hobisch, Alfred ^a,c   Culig, Zoran ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c General Hospital Feldkirch   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN E; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROTEIN P27; RETINOBLASTOMA PROTEIN; STAT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CACHEXIA; CANCER CELL CULTURE; CANCER CONTROL; CELL GROWTH; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE TUMOR; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VOLUME; WESTERN BLOTTING;

EID: 0037331278     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)63859-X     Document Type: Article

References (54)

1. Angelo LS, Talpaz M, Kurzrock R: Autocrine interleukin-6 production in renal cell carcinoma: evidence for the involvement of p53. Cancer Res 2002, 62:932-940
2. Frassanito MA, Cusmai A, Iodice G, Dammacco F: Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis. Blood 2001, 97:483-489
3. Lu C, Vickers MF, Kerbel RS: Interleukin-6: a fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression. Proc Natl Acad Sci USA 1992, 89:9215-9219
4. Twillie DA, Eisenberger MA, Carducci MA, Hselh W-S, Kim WY, Simons JW: Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology 1995, 45:542-549
5. Giri D, Ozen M, Ittmann M: Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 2001, 159:159-165
6. Chung TD, Yu JJ, Kong TA, Spiotto MT, Lin JM: Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell lines Prostate 2000, 42:1-7
7. Degeorges A, Tatoud R, Fauvel Lafeve F, Podgorniak MP, Millot G, de Cremoux P, Calvo F: Stromal cells from human benign prostate hyperplasia produce a growth-inhibitory factor for LNCaP prostate cancer cells, identified as interleukin-6. Int J Cancer 1996, 68:207-214
8. Ritchie CK, Andrews LR, Thomas KG, Tindall DJ, Fitzpatrick LA: The effects of growth factors associated with osteoblasts on prostate carcinoma proliferation and chemotaxis: implications for the development of metastatic disease. Endocrinology 1997, 138:1145-1150
9. Levesque E, Beaulieu M, Guillemette C, Hum DW, Belanger A: Effect of interleukins on UGT2B15 and UGT2B17 steroid uridine diphosphate-glucuronosyltransferase expression and activity in the LNCaP cell line. Endocrinology 1998, 139:2375-2381
10. Spiotto MT, Chung TD: STAT3 mediates IL-6-induced growth inhibition in the human prostate cancer cell line LNCaP. Prostate 2000, 42:88-98
11. Mori S, Murakami-Mori K, Bonavida B: Interleukin-6 induces G1 arrest through induction of p27 (Kip1), a cyclin-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells. Biochem Biophys Res Commun 1999, 257:609-614
12. Deeble PD, Murphy DJ, Parsons SJ, Cox ME: Interleukin-6 and cyclic-AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells. Mol Cell Biol 2001, 21:8471-8482
13. Qiu Y, Ravi L, Kung H-J: Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells. Nature 1998, 393:83-85
14. Okamoto M, Lee C, Oyasu R: Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro Cancer Res 1997, 57:141-146
15. Lou W, Ni Z, Dyer K, Tweardy DJ, Gao AC: Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway. Prostate 2000, 42:239-242
16. Hobisch A, Eder IE, Putz T, Horninger W, Bartsch G, Klocker H, Culig Z: Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 1998, 58:4640-4645
17. Lin DL, Whitney MC, Yao Z, Keller ET: Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression. Clin Cancer Res 2001, 7:1773-1781
18. Hobisch A, Ramoner R, Fuchs D, Godoy-Tundidor S, Bartsch G, Klocker H, Culig Z: Prostate cancer cells (LNCaP) generated after long-term interleukin-6 treatment express interleukin-6 and acquire an interleukin-6-partially resistant phenotype. Clin Cancer Res 2001, 7:2941-2948
19. Bradford M: A rapid and sensitive method for the quantitation of microgram quantities of protein using the principle of protein-dye binding. Anal Biochem 1978, 72:248-254
20. Hofman K, Swinnen JV, Verhoeven G, Heyns W: E2F activity is biphasically regulated by androgens in LNCaP cells. Biochem Biophys Res Commun 2001, 283:97-101
21. Spiotto MT, Chung TD: STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells. Prostate 2000, 42:186-195
22. Okuno Y, Takahashi T, Suzuki A, Fukumoto M, Nakamura K, Fukui H, Koishihara Y, Ohsugi Y, Imura H: Acquisition of growth autonomy and tumorigenicity by an interleukin 6-dependent human myeloma cell line transfected with interleukin 6 cDNA. Exp Hematol 1992, 20:395-400
23. Jee SH, Shen SC, Chiu HC, Tsai WL, Kuo ML: Overexpression of interleukin-6 in human basal cell carcinoma cell lines increases antiapoptotic activity and tumorigenic potency. Oncogene 2001, 20:198-208
24. Okamoto M, Oyasu R: Effect of transfected interleukin-6 in non-tumorigenic and tumorigenic rat urothelial cell lines. Int J Cancer 1996, 68:616-621
25. Lu C, Sheehan C, Rak JW, Chambers CA, Hozumi N, Kerbel RS: Endogenous interleukin-6 can function as an in vivo growth-stimulatory factor for advanced-stage human melanoma cells. Clin Cancer Res 1996, 2:1417-1425
26. Armstrong CA, Murray N, Kennedy M, Koppula SV, Tara D, Ansel JC: Melanoma-derived interleukin 6 inhibits in vivo melanoma growth J Invest Dermatol 1994, 102:278-284
27. Smith PC, Keller ET: Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice. Prostate 2001, 48:47-53
28. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC, Chung LW: Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 1994, 54:2577-2581
29. Stratton MS, Sirvent H, Udayakumar TS, Nagle RB, Bowden GT: Expression of the matrix metalloproteinase promatrilysin in coculture of prostate carcinoma cell lines. Prostate 2001, 48:206-209
30. Stephenson RA, Dinney CP, Gohji K, Ordonez NG, Killion JJ, Fidler IJ: Metastatic model for human prostate cancer using orthotopic implantation in nude mice. J Natl Cancer Inst 1992, 84:951-957
31. Rembrink K, Romijn JC, van der Kwast TH, Rubben H, Schroder FH: Orthotopic implantation of human prostate cancer cell lines: a clinically relevant animal model for metastatic prostate cancer Prostate 1997, 31:168-174
32. Tamura S, Ouchi KF, Mori K, Endo M, Matsumoto T, Eda H, Tanaka Y, Ishitsuka H, Tokita H, Yamaguchi K: Involvement of human interleukin 6 in experimental cachexia induced by a human uterine cervical carcinoma xenograft. Clin Cancer Res 1995, 1:1353-1358
33. Müller H, Lukas J, Schneider A, Warthoe P, Bartek J, Eilers M, Strauss M: Cyclin D1 expression is regulated by the retinoblastoma protein. Proc Natl Acad Sci USA 1994, 91:2945-2949
34. Urashima M, Ogata A, Chauhan D, Vidriales MB, Teoh G, Hoshi Y, Schlossman RL, DeCaprio JA, Anderson KC: Interleukin-6 promotes multiple myeloma cell growth via phosphorylation of retinoblastoma protein. Blood 1996, 88:2219-2227
35. Santhanam U, Ray A, Sehgal PB: Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc Natl Acad Sci USA 1991, 88:7605-7609
36. Bartek J, Lukas J, Bartkova J: Perspective: defects in cell cycle control and cancer. J Pathol 1999, 187:95-99
37. Phillips SM, Barton CM, Lee SJ, Morton DG, Wallace DM, Lemoine NR, Neoptolemos JP: Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumorigenesis. Br J Cancer 1994, 70:1252-1257
38. Hobisch A, Rogatsch H, Hittmair A, Fuchs D, Bartsch GJ, Klocker H, Bartsch G, Culig Z: Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. J Pathol 2000, 191:239-244
39. Cordon-Cardo C, Koff A, Drobnjak M, Capodieci P, Osman I, Millard SS, Gaudin PB, Fazzari M, Zhang ZF, Massague JF, Scher HI: Distinct altered patterns of p27kip1 gene expression in benign prostate hyperplasia and prostate carcinoma. J Natl Cancer Inst 1998, 90:1284-1291
40. Cheng L, Lloyd RV, Weaver AL, Pisansky TM, Cheville JC, Ramnani DM, Leibovich BC, Blute ML, Zincke H, Bostwick DG: The cell cycle inhibitors p21WAF1 and p27KIP1 are associated with survival in patients treated by salvage prostatectomy after radiation therapy. Clin Cancer Res 2000, 6:1896-1899
41. Agus DB, Cordon-Cardo C, Fox W, Drobnjak M, Koff A, Golde DW, Scher HI: Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst 1999, 91:1869-1876
42. Böhm M, Schulte U, Funk JO, Raghunath M, Behrmann I, Kortylewski M, Heinrich PC, Kues T, Luger TA, Schwarz T: Interleukin-6-resistant melanoma cells exhibit reduced activation of STAT3 and lack of inhibition of cyclin E-associated kinase activity. J Invest Dermatol 2001, 117:132-140
43. Florenes VA, Lu C, Bhattacharya N, Rak J, Sheehan C, Slingerland JM, Kerbel RS: Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21WAF1/CIP1 is lost during progression of human malignant melanoma. Oncogene 1999, 18:1023-1032
44. Yu C, Wang L, Khaletskly A, Farrar WL, Larner A, Colburn NH, Li JJ: STAT3 activation is required for interleukin-6 induced transformation in tumor-promotion sensitive mouse skin epithelial cells. Oncogene 2002, 21:3949-3960
45. Syed V, Ulinski G, Mok SC, Ho SM: Reproductive hormone-induced, STAT3-mediated interleukin-6 action in normal and malignant human ovarian surface epithelial cells J Natl Cancer Inst 2002, 94:617-629
46. Horiguchi A, Oya M, Marumo K, Murai M: STAT3, but not ERKs, mediates the IL-6-induced proliferation of renal cancer cells, ACHN and 769P. Kidney Int 2002, 61:926-938
47. Pansky A, Hildebrand P, Fasler-Kan E, Baselgia L, Ketterer S, Beglinger C, Helm MH: Defective Jak-STAT signal transduction pathway in melanoma cells resistant to growth inhibition by interferon-alpha. Int J Cancer 2000, 85:720-725
48. Zhang J, Shen B, Li Y, Sun Y: STAT3 exerts two-way regulation in the biological effects of IL-6 in M1 leukemia cells. Leuk Res 2001, 25:463-472
49. Terstegen L, Gatsios P, Bode JG, Schaper F, Heinrich PC, Graeve L: The inhibition of interleukin-6-dependent STAT activation by mitogen-activated protein kinases depends on tyrosine 759 in the cytoplasmic tail of glycoprotein 130 J Biol Chem 2000, 275:18810-18817
50. Campbell CL, Jiang Z, Savarese DM, Savarese TM: Increased expression of the interleukin-11 receptor and evidence of STAT3 activation in prostate carcinoma. Am J Pathol 2001, 158:25-32
51. Dhir R, Ni Z, Lou W, DeMiguel F, Grandis JR, Gao AC: Stat3 activation in prostatic carcinomas. Prostate 2002, 51:241-246
52. Guo C, Luttrell LM, Price DT: Mitogenic signaling in androgen sensitive and insensitive prostate cancer cell lines. J Urol 2000, 163:1027-1032
53. Chen T, Cho RW, Stork PJ, Weber MJ: Elevation of cyclic adenosine 3′5′-monophosphate potentiates activation of mitogen-activated protein kinase by growth factors in LNCaP prostate cancer cells. Cancer Res 1999, 59:213-218
54. Putz T, Culig Z, Eder IE, Nessler-Menardi C, Bartsch G, Grunicke H, Überall F, Klocker H: Epidermal growth factor receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines. Cancer Res 1999, 59:227-233